EnteroMedics Inc (NASDAQ:ETRM), the developer of medical devices using neuroblocking therapy to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the launch …
In a research report published Tuesday, Canaccord Genuity analyst William Plovanic maintained a Buy rating on shares of EnteroMedics Inc (NASDAQ:ETRM), while reducing the …
EnteroMedics Inc (NASDAQ:ETRM), the developer of medical devices using neuroblocking therapy to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that 18 …
EnteroMedics Inc (NASDAQ:ETRM), a developer and manufacturer of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, today …
EnteroMedics Inc (NASDAQ:ETRM), a developer and manufacturer of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, announced …
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has increased $5.78 in mid-day trading to $8.
Canaccord Genuity’s healthcare analyst William Plovanic weighed in with an optimistic view on EnteroMedics Inc (NASDAQ:ETRM), after the company provided an update regarding the training and …
Healthcare company Enteromedics Inc. (NASDAQ: ETRM) reported its fourth quarter 2014 earnings result on Wednesday, February 18th after market close, coming in slightly ahead of …
Roth Capital’s healthcare analyst Chris Lewis weighed in today with a research report on Enteromedics Inc. (NASDAQ:ETRM), reiterating a Buy rating and reducing the price target …
In a research report released this morning, Canaccord Genuity analyst William Plovanic reiterated a Buy rating on EnteroMedics Inc (NASDAQ:ETRM) with a $4 price target, …
